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Methods 
Study Design 
ERICA is a longitudinal, observational study with phenotypic assessments being conducted 
at baseline, and follow-up via 6-monthly questionnaires for a period of 3 years. The data 
presented here is cross-sectional data from the baseline assessments. 
 
The study was powered on the basis of a tertile analysis of aPWV and QMVC. Assuming an 
average aPWV of 10 (standard deviation (SD) 1.0m/s) and a minimal clinically relevant 
difference of 0.4m/s, 230 patients per tertile provide 90% power at p<0.01 to detect this 
difference between the top and bottom quartiles. Assuming an average QMVC of 32 (SD 
8kg, 220 patients per tertile will provide 90% power at a significance of p <0.01 in order to 
detect the minimum clinical difference of 3kg between the top and bottom tertiles. Allowing 
for a 10% dropout rate and incomplete datasets, approximately 800 patients were required.   
 
 
Study Assessments 
We measured demographics, height, weight, fat-free mass (single-frequency (50kHz) 
bioelectrical impedance analysis via TANITA BC 418MA (Tanita Corporation, Tokyo, Japan), 
post-bronchodilator spirometry, health-related quality of life questionnaires (Medical 
Research Council dyspnoea score, St George’s Respiratory Questionnaire and COPD 
Assessment Test), peripheral blood pressure and Short Physical Performance Battery (SPPB). 
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SPPB is A composite assessment of lower extremity function comprising standing balance, 4 
meter gait speed and sitting-to-standing speed, with a maximum possible total score of 12 
(1). Lower scores indicate increasing frailty. Six minute walk distance was measured in 
accordance with the guidelines of the American Thoracic Society (2) except that a practice 
walk was not performed due to time constraints. Subjects fasted for >4 hours and refrained 
from medications for >6 hours prior to aPWV measurements and venepuncture, the latter 
being used for plasma fibrinogen, white cell count (WCC) and high sensitivity C-reactive 
protein (hsCRP) measurements.  
  
 
Fibrinogen 
Whole blood was collected into a vacutainer tube (sodium citrate as the anticoagulant), and 
plasma fibrinogen was measured in fresh plasma samples using an automated, modified 
Clauss method (HemosIL Fibrinogen-C XL, Instrumentation Laboratories(3)).  The assay 
method is a direct measurement of functional fibrinogen and is the method most commonly 
used in clinical laboratories. 
 
Aortic Pulse Wave Velocity (aPWV) 
Following 10 minutes of supine rest, brachial blood pressure was measured three times, and 
an average of the final readings used for analysis. APWV was measured via the SphygmoCor 
device (AtCor, West Ryde, Australia), between the carotid and femoral arteries, using a 
piezoelectric tonometer placed over the artery and ECG gating, as previously described in 
detail (4). 
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Quadriceps Maximal Volitional Contraction 
QMVC force was measured using the technique of Edwards et al (5) and expressed as a 
percentage of predicted values using the equations developed by Seymour and co-workers 
(6).  Patients were verbally encouraged to make a maximal contraction by pushing against an 
inextensible strap placed above the ankle.  The manoeuvre was repeated six times with a 
minimum 20 second interval between efforts. We used the highest value of contraction which 
could be sustained for 1 second for analysis. 
 
Exacerbations and Medications 
For this study, we have defined exacerbations as self-reported increase in COPD symptoms 
that required treatment with antibiotics and/ or steroids and severe exacerbations as those 
that require hospital admission.  
 
There are no prohibited medications in the study. All subjects continued their routine 
prescribed medications throughout the study and the patient’s physician may offer 
treatments (e.g. medication change, rehabilitation) in line with the patients’ needs.   
 
 
Statistical analysis 
Linear regression analyses were used to estimate the differences between the mean in the 
overall study population and the mean in each group, for continuous outcome variables.  To 
compare the results of binary outcome variables across the phenotypic groups, logistic 
regression was used to estimate odds ratios. To compare the MRC score across the 
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phenotypic groups, proportional odds logistic regression (POLR) was used to estimate odds 
ratios. When estimating odds ratios, the group with neither muscle weakness nor high 
cardiovascular risk was taken as the baseline group. Correction was not made for multiple 
comparisons. 
 
Multiple linear regression analyses were conducted to estimate the dependence of QMVC 
and aPWV on each inflammatory biomarker, with adjustment for known or expected 
confounders. Non-normally distributed variables were log transformed prior to analysis. The 
full study population was included in the main analysis. 
Sensitivity analyses were carried out that excluded subjects with simultaneously elevated 
hsCRP (>20 mg/L) and WCC (>11.0 x 109/L), to exclude the possibility that data were skewed 
by participants with subclinical exacerbations. 
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Results 
eTable 1 Variables with missing data 
Variable Number of subjects with missing data 
Smoking history 11 
Height 6 
Weight 12 
Body mass index 12 
Fat free mass 35 
Forced expiratory volumes in 1 second 4 
Forced vital capacity 4 
Quadriceps maximal volitional contraction 32 
Short physical performance battery 12 
6 minute walk distance 36 
Supine heart rate 56 
Supine mean arterial pressure 15 
Pulse wave velocity 65 
Fibrinogen 13 
High sensitivity-C-Reactive Protein 20 
White cell count 15 
Medical Research Council dyspnoea score 10 
COPD Assessment Test score 10 
SGRQ total score 24 
Exacerbation history 104 
Diabetes history 8 
Antihypertensive therapy 11 
Cholesterol lowering therapy 15 
Previous history of myocardial infarction 10 
 
eTable 1: Number of subjects with missing data per variable in total ERICA cohort (n = 729) 
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eTable 2 Aortic pulse wave velocity and fibrinogen (n=635) 
Variable Estimate Standard error P value 95% Confidence 
Interval 
Log fibrinogen 0.18 0.37 0.64 -0.54, 0.90 
Age (years) 0.13 0.01 <0.0001 0.11, 0.16 
Gender 0.45 0.20 0.028 0.06, 0.86 
Supine heart rate 0.05 0.01 <0.0001 0.17, 1.56 
Supine mean arterial 
pressure 
0.06 0.01 <0.0001 -0.14, 1.00 
Current smoker -0.19 0.20 0.33 -1.63, -0.22 
Smoking pack year 
history 
0.001 0.003 0.65 -0.03, 1.58 
FEV1 (L) -0.13 0.20 0.52 0.03, 0.06 
Diabetes 0.90 0.29 <0.01 0.04, 0.08 
Previous heart attack -0.003 0.34 0.99 -0.56, 0.21 
Anti-hypertensive 
therapy 
-0.02 0.20 0.92 -0.005, 0.007 
Cholesterol lowering 
therapy 
0.31 0.22 0.14 0.38, 1.52 
Site 2 vs site 1 0.86 0.35 0.03 -0.61, 0.75 
Site 3 vs site 1 0.46 0.29 0.12 -0.50, 0.26 
Site 4 vs site 1 -0.92 0.36 0.01 -0.40, 0.38 
Site 5 vs site 1 0.77 0.41 0.06 -0.16, 0.67 
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 eTable 2: Linear regression analysis for associations with cardiovascular manifestation, as 
measured by aortic pulse wave velocity, in subjects with COPD (n=635). Age, gender, supine 
heart rate, supine mean arterial pressure and the presence of diabetes are significantly 
associated with aortic pulse wave velocity (p < 0.0001, p = 0.028, p<0.0001, p<0.0001 and 
p<0.01 respectively), but fibrinogen is not associated with aortic pulse wave velocity (p = 
0.64). Site 1 is set as the index, comparator site for remaining sites. 
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eTable 3 Quadriceps maximal volitional contraction and fibrinogen (n=656) 
Variable Estimate Standard 
error 
P value 95% Confidence 
Interval 
Log fibrinogen -0.33 1.47 0.82 -3.41, 2.24 
Age (years) -0.17 0.05 <0.001 -0.26, -0.08 
Gender 6.4 1.05 <0.0001 4.20, 8.30 
Current smoker -0.17 0.78 0.79 -3.77, 1.71 
Fat free mass 0.37 0.05 <0.0001 -4.93, -0.34 
Height -0.12 0.06 0.061 -2.66, 2.82 
FEV1 4.7 0.83 <0.0001 -3.45, 2.87 
Site 2 vs site 1 -1.14 1.4 0.42 -1.73, 1.31 
Site 3 vs site 1 -2.68 1.17 0.023 0.27, 0.48 
Site 4 vs site 1 0.07 1.40 0.96 -0.25, 0.01 
Site 5 vs site 1 -0.32 1.61 0.84 3.09, 6.31 
 
eTable 3: Linear regression analysis for determinants of quadriceps maximal volitional 
contraction in subjects with COPD (n=656). Age, gender, fat-free mass and FEV1 emerge as 
significantly associated with quadriceps weakness (p <0.001, p <0.0001, p <0.0001 and 
p<0.0001 respectively), with fibrinogen not emerging as a significant association (p=0.82). 
Site 1 is set as the index, comparator site for remaining sites. 
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eTable 4 Pulse wave velocity and hsCRP (n = 631) 
Variable Estimate Standard error P value 
Log hsCRP 0.08 0.08 0.31 
Age (years) 0.14 0.01 <0.0001 
Gender 0.46 0.20 0.03 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.18 0.20 0.36 
Smoking pack year history 0.001 0.003 0.78 
FEV1 (L) -0.15 0.20 0.45 
Diabetes 0.85 0.30 0.005 
Previous heart attack -0.01 0.35 0.99 
Anti-hypertensive therapy 0.03 0.2 0.87 
Cholesterol lowering therapy 0.33 0.22 0.13 
Site 2 0.76 0.36 0.03 
Site 3 0.35 0.29 0.22 
Site 4 -0.98 0.37 0.01 
Site 5 0.68 0.41 0.10 
 
eTable 4: Linear regression analysis for determinants of arterial stiffness, as measured by 
pulse wave velocity, with hs-CRP as the marker of systemic inflammation. Site 1 is the index, 
comparator site for remaining sites.  
  
11 
 
eTable 5 Pulse wave velocity and white blood count (n=636) 
Variable Estimate Standard error P value 
Log WCC 0.36 0.33 0.27 
Age (years) 0.14 0.01 <0.0001 
Gender 0.44 0.21 0.03 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.17 0.20 0.41 
Smoking pack year history 0.001 0.003 0.74 
FEV1 (L) -0.16 0.20 0.41 
Diabetes 0.86 0.29 0.002 
Previous heart attack -0.03 0.34 0.93 
Anti-hypertensive therapy -0.01 0.20 0.99 
Cholesterol lowering therapy 0.36 0.22 0.09 
Site 2 0.75 0.35 0.03 
Site 3 0.35 0.29 0.22 
Site 4 -1.00 0.36 0.01 
Site 5 0.72 0.41 0.08 
 
eTable 5: Linear regression analysis for determinants of arterial stiffness, as measured by 
pulse wave velocity, with white cell count as the marker of systemic inflammation. Site 1 is 
the index, comparator site for remaining sites.  
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eTable 6 Quadriceps maximal volitional contraction and hsCRP (n=648) 
Variable Estimate Standard error P value 
Log hsCRP -0.54 0.32 0.09 
Age (years) -0.19 0.05 <0.0001 
Gender 6.50 1.04 <0.0001 
Current smoker 0.02 0.77 0.98 
Fat free mass 0.39 0.05 <0.0001 
Height -0.13 0.06 0.04 
FEV1 4.23 0.82 <0.0001 
Site 2 -0.99 1.38 0.48 
Site 3 -2.57 1.16 0.03 
Site 4 0.28 1.39 0.84 
Site 5 -0.24 1.59 0.88 
 
eTable 6: Linear regression analysis for determinants of quadriceps weakness, as measured 
by quadriceps maximal volitional contraction, with hs-CRP as the marker of systemic 
inflammation. Site 1 is the index, comparator site for remaining sites.  
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eTable 7 Quadriceps maximal volitional contraction and white blood count (n=657) 
Variable Estimate Standard error P value 
Log WCC -0.99 1.28 0.44 
Age (years) -0.18 0.05 <0.001 
Gender 6.52 1.05 <0.0001 
Current smoker -0.08 0.79 0.92 
Fat free mass 0.37 0.06 <0.0001 
Height -0.13 0.06 0.05 
FEV1 4.67 0.82 <0.0001 
Site 2 -1.14 1.39 0.97 
Site 3 -2.71 1.16 0.02 
Site 4 0.05 1.39 0.97 
Site 5 -0.15 0.79 0.92 
 
eTable 7: Linear regression analysis for determinants of quadriceps weakness, as measured 
by quadriceps maximal volitional contraction, with white cell count as the marker of 
systemic inflammation. Site 1 is the index, comparator site for remaining sites. 
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eTable 8 Pulse wave velocity and fibrinogen in sub-population (n=630) 
Variable Estimate Standard error P value 
Log fibrinogen 0.32 0.38 0.39 
Age (years) 0.14 0.01 <0.0001 
Gender 0.44 0.20 0.03 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.17 0.20 0.40 
Smoking pack year history 0.002 0.003 0.62 
FEV1 (L) -0.09 0.20 0.66 
Diabetes 0.88 0.29 0.002 
Previous heart attack 0.004 0.34 0.99 
Anti-hypertensive therapy -0.02 0.20 0.94 
Cholesterol lowering therapy 0.29 0.22 0.19 
Site 2 0.85 0.35 0.02 
Site 3 0.44 0.29 0.13 
Site 4 -0.85 0.36 0.02 
Site 5 0.81 0.41 0.05 
 
eTable 8: Linear regression analysis for determinants of arterial stiffness, as measured by 
pulse wave velocity, with fibrinogen as the marker of systemic inflammation in a sub-
population where subjects with simultaneously elevated hs-CRP of >20 mg/L and WCC of 
>11 x 109/L were excluded from the analysis. Site 1 is the index, comparator site for 
remaining sites. 
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eTable 9 Pulse wave and hsCRP in sub-population (n=626) 
Variable Estimate Standard error P value 
Log hsCRP 0.15 0.09 0.08 
Age (years) 0.14 0.01 <0.0001 
Gender 0.45 0.21 0.03 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.15 0.20 0.46 
Smoking pack year history 0.001 0.003 0.76 
FEV1 (L) -0.12 0.20 0.56 
Diabetes 0.82 0.30 0.007 
Previous heart attack -0.005 0.34 0.99 
Anti-hypertensive therapy -0.03 0.20 0.89 
Cholesterol lowering therapy 0.30 0.22 0.16 
Site 2 0.74 0.36 0.04 
Site 3 0.34 0.29 0.25 
Site 4 -0.90 0.37 0.02 
Site 5 0.73 0.41 0.08 
 
eTable 9: Linear regression analysis for determinants of arterial stiffness, as measured by 
pulse wave velocity, with hsCRP as the marker of systemic inflammation in a sub-population 
where subjects with simultaneously elevated hs-CRP of >20 mg/L and WCC of >11 x 109/L 
were excluded from the analysis. Site 1 is the index, comparator site for remaining sites. 
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eTable 10 Pulse wave velocity and white cell count in sub-population (n=631) 
Variable Estimate Standard error P value 
Log WCC 0.52 0.34 0.12 
Age (years) 0.14 0.01 <0.0001 
Gender 0.43 0.21 0.04 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.15 0.20 0.46 
Smoking pack year history 0.001 0.003 0.70 
FEV1 (L) -0.13 0.20 0.51 
Diabetes 0.83 0.29 0.005 
Previous heart attack -0.02 0.34 0.96 
Anti-hypertensive therapy 0.001 0.20 1.00 
Cholesterol lowering therapy 0.33 0.22 0.12 
Site 2 0.74 0.35 0.04 
Site 3 0.35 0.29 0.23 
Site 4 -0.92 0.36 0.01 
Site 5 0.78 0.42 0.06 
 
eTable 10: Linear regression analysis for determinants of arterial stiffness, as measured by 
pulse wave velocity, with white cell count as the marker of systemic inflammation in a sub-
population where subjects with simultaneously elevated hs-CRP of >20 mg/L and WCC of 
>11 x 109/L were excluded from the analysis. Site 1 is the index, comparator site for 
remaining sites. 
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eTable 11 Quadriceps maximal volitional contraction and fibrinogen (n=648) in sub-
population 
Variable Estimate Standard error P value 
Log fibrinogen -0.21 1.50 0.89 
Age (years) -0.18 0.05 <0.0001 
Gender 6.48 1.06 <0.0001 
Current smoker -0.23 0.79 0.77 
Fat free mass 0.37 0.06 <0.0001 
Height -0.13 0.06 0.05 
FEV1 4.60 0.83 <0.0001 
Site 2 -1.23 1.41 0.38 
Site 3 -2.77 1.18 0.02 
Site 4 -0.03 1.42 0.98 
Site 5 -0.36 1.64 0.83 
 
eTable 11: Linear regression analysis for determinants of quadriceps weakness, as measured 
by quadriceps maximal volitional contraction, with fibrinogen as the marker of systemic 
inflammation in a sub-population where subjects with simultaneously elevated hs-CRP of 
>20 mg/L and WCC of >11 x 109/L were excluded from the analysis. Site 1 is the index, 
comparator site for remaining sites. 
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eTable 12 Quadriceps maximal volitional contraction and hsCRP (n=640) in sub-population 
Variable Estimate Standard error P value 
Log hsCRP -0.55 0.34 0.10 
Age (years) -0.19 0.05 <0.0001 
Gender 6.56 1.05 <0.0001 
Current smoker -0.05 0.78 0.95 
Fat free mass 0.39 0.06 <0.0001 
Height -0.14 0.06 0.04 
FEV1 4.14 0.83 <0.0001 
Site 2 -1.05 1.39 0.45 
Site 3 -2.63 1.17 0.02 
Site 4 0.14 1.42 0.92 
Site 5 -0.32 1.63 0.84 
 
eTable 12: Linear regression analysis for determinants of quadriceps weakness, as measured 
by quadriceps maximal volitional contraction, with hsCRP as the marker of systemic 
inflammation in a sub-population where subjects with simultaneously elevated hs-CRP of 
>20 mg/L and WCC of >11 x 109/L were excluded from the analysis. Site 1 is the index, 
comparator site for remaining sites. 
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eTable 13 Quadriceps maximal volitional contraction and white cell count (n=649) in sub-
population 
Variable Estimate Standard error P value 
Log WCC -0.80 1.33 0.55 
Age (years) -0.18 0.05 <0.0001 
Gender 6.58 1.06 <0.0001 
Current smoker -0.16 0.80 0.84 
Fat free mass 0.37 0.06 <0.0001 
Height -0.13 0.06 0.04 
FEV1 4.59 0.83 <0.0001 
Site 2 -1.21 1.40 0.39 
Site 3 -2.77 1.17 0.02 
Site 4 -0.05 1.41 0.97 
Site 5 -0.19 1.65 0.91 
 
eTable 13: Linear regression analysis for determinants of quadriceps weakness, as measured 
by quadriceps maximal volitional contraction, with white cell count as the marker of 
systemic inflammation in a sub-population where subjects with simultaneously elevated hs-
CRP of >20 mg/L and WCC of >11 x 109/L were excluded from the analysis. Site 1 is the 
index, comparator site for remaining sites. 
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eFigure 1 Distribution of cardiovascular and muscular manifestations in COPD 
 
eFigure 1 Distribution of cardiovascular and muscular manifestations in COPD (total 
n=617). Group ‘Neither’ (n=194) represents subjects with neither elevated aortic pulse wave 
velocity nor skeletal muscle weakness. Group ‘Muscle’ (n=137) represents subjects with 
skeletal muscle weakness alone. Group ‘Cardiovascular’ (n=154) represents subjects with 
cardiovascular manifestation, defined as elevated aortic stiffness, alone, and group ‘Both’ 
(n=132) contains subjects demonstrating both skeletal muscle weakness and elevated aortic 
stiffness. Skeletal muscle weakness was defined according to predicted quadriceps maximal 
volitional contraction, based on equations developed by Seymour et al 2 and elevated 
arterial stiffness was defined as an aortic pulse wave velocity of >10 m/s.  
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eFigure 2 Relationship between quadriceps strength and airflow limitation in COPD 
subjects 
 
eFigure2 Relationship between quadriceps strength and airflow limitation in COPD 
subjects (n = 694) 
Scatterplot showing a weak but significant correlation between % predicted quadriceps 
maximal volitional contraction (QMVC % predicted) and % predicted forced expiratory 
volume in 1 second (FEV1 % Predicted) in COPD subjects in the ERICA cohort 
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